Master sales trainer and coach Al Simon of Sandler Training interviews local business owners and sales professionals about some of the sales challenges they face and things they can do to increase sales for their organizations. He also provides a timely sales tip to help you reach your goals at the end of every show in his "Ask Al" segment.
All content for Simon Says is the property of Podgo and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Master sales trainer and coach Al Simon of Sandler Training interviews local business owners and sales professionals about some of the sales challenges they face and things they can do to increase sales for their organizations. He also provides a timely sales tip to help you reach your goals at the end of every show in his "Ask Al" segment.
SIMON SAYS, LET’S TALK BUSINESS: David Dodd with GeoVax
Simon Says
30 minutes 54 seconds
2 months ago
SIMON SAYS, LET’S TALK BUSINESS: David Dodd with GeoVax
David Dodd/GeoVaxGeoVax Labs is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease program includes GEO-CM04S1, a next-generation Covid-19 vaccine designed for the growing population of high-risk immunocompromised patients with cancers, autoimmune conditions, and neuromuscular diseases. Currently in two Phase 2 clinical trials, CM04S1 is being evaluated as a Covid-19 vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient. In addition, CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. A synergistic program is underway with the rights from the US NIH to make GeoVax the first U.S. supplier of the vaccine vector MVA for protection against Monkeypox and Smallpox. GEO-CM04S1 GeoVax has a solid financial foundation, is listed on Nasdaq (“GOVX”), with a leadership team who have driven significant value creation across multiple life science companies over the past several decades.
Simon Says
Master sales trainer and coach Al Simon of Sandler Training interviews local business owners and sales professionals about some of the sales challenges they face and things they can do to increase sales for their organizations. He also provides a timely sales tip to help you reach your goals at the end of every show in his "Ask Al" segment.
